Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
-
- STATUS
- Recruiting
-
- participants needed
- 124
-
- sponsor
- CSL Behring
Updated on 21 January 2021
Trial Registration Coordinator
Primary Contact
Northeast Iowa Medical Education Foundation (2.7 mi away) Contact
+11 other locationpneumonia
FIO2
pao2
covid-19
pao2/fio2 ratio
SARS
chest ct
oximetry
coronavirus infection
Summary
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)
Details
| Treatment | Placebo, Garadacimab, Factor XIIa Antagonist Monoclonal Antibody |
|---|---|
| Clinical Study Identifier | NCT04409509 |
| Sponsor | CSL Behring |
| Last Modified on | 21 January 2021 |
How clear was the trial content above?
Hard
Easy
Adding a note
Select a piece of text and start making personal notes.
Similar trials to consider
Loading...
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer